# A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07328217/  
OnCo record `nct07328217` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GW5282 in advanced solid tumours, run by Dizal Pharmaceuticals, now recruiting.

## Summary

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07328217 by Dizal Pharmaceuticals, with 203 participants planned, started 2026-01-29 and due to reach its primary completion in 2028-12. Interventions recorded: GW5282.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07328217
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of GW5282 in Participants With Advanced Solid Tumors (BEI-DOU2)
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 203

## Sources

- ClinicalTrials.gov NCT07328217: https://clinicaltrials.gov/study/NCT07328217

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07328217.json